ETNB Bathi resik saben saham sajrone 12 wulan pungkasan 89bio.com

Earnings per share over the last 12 months for 89bio, Inc. (ETNB) reflect a trend where the metric reached -3.58. The current trend is driven by a lack of operating leverage due to the testing phase. R&D efficiency is increasing through digital biochemical screening systems, while the retention of leading pharmacologists is secured by academic freedom and equity options, strengthening the company's potential for developing liver disease medications.

ETNB (89bio Pharma) riwayat Bathi resik saben saham (EPS TTM) saka 04.07.2022 nganti 15.11.2025

Rincian analitis lan laporan data perusahaan 89bio Inc (ETNB)

- rega saham lan target rega konsensus:

Rega saham 89bio, Inc.|ETNB - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Biji pasar 89bio, Inc.|ETNB - Total Nilai Bisnis

- indikator nilai aset resik miturut neraca:

Nilai Buku saben Saham 89bio|ETNB - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku 89bio.com|ETNB - Aset Agregat Perusahaan

- rincian struktur utang lan likuiditas bisnis:

- indikator pendapatan resik lan kelipatan nilai:

ETNB - Penghasilan resik|Penghasilan resik sing dikarepake 89bio, Inc.|ETNB - Periode bali modal bisnis|Pangali Forward P/E 89bio|ETNB - Rasio rega marang bathi tumrap wutah|Pangali EV/EBITDA 89bio, Inc.|ETNB - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan 89bio|ETNB - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan 89bio.com|ETNB - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep 89bio, Inc.

- data dodolan lan asil:

ETNB - Pendapatan reged perusahaan|Prakiraan pendapatan perusahaan 89bio, Inc.|ETNB - Rasio kapitalisasi marang pendapatan|Multiplikator Forward P/S 89bio, Inc.

Pambiji fundamental perusahaan:89bio, Inc. (ETNB)

This indicator measures the actual efficiency of profit generation per share annually, excluding distortions from share issuances or buybacks. By analyzing the annual net income per share trend, an investor identifies the reversal point of fundamental momentum, which is critical for 89bio, Inc. (ETNB), as its future pricing power and high margins depend on the successful market launch of its therapy.

Pesaing 89bio, Inc.